 JENA, GERMANY, Nov. 03, 2021 GLOBE NEWSWIRE -- InflaRx Nasdaq: IFRX, a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, will present a corporate overview during a fireside chat at the Credit Suisse 30th Annual Healthcare Conference. 